KEAP1 inactivation mutations are associated with alterations in the NSCLC immune microenvironment, and the KK type shows a poor response to immune checkpoint blockade (ICB) therapy [83, 84]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.